ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Unveiling the potential of solid lipid nanoparticles of apigenin-Cu(II) coordinated nanocomplex in colon cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To engineer biocompatible, colon-targeted delivery vehicle utilizing octadecanol-dextran (Odl-Dex)-coated apigenin-copper (Apg-Cu(II)) loaded solid lipid nanoparticles (SLNs). The main research study was based on enzyme-responsive system to prevent premature gastrointestinal drug degradation while maximizing localised therapeutic potential against colon cancer. The Apg-Cu(II) SLNs were formulated via hot-melt emulsification and surface-coated with Odl-Dex. The nanoparticles were characterised for particle size, surface charge, and entrapment efficiency (%). Enzyme-triggered release was evaluated using simulated gastrointestinal fluid with dextranase. In vitro cytotoxicity and cellular apoptosis were assessed on human HCT-116 colon cancer cells, followed by in vivo pharmacokinetic evaluation in Wistar rats to determine oral bioavailability. The optimised Odl-Dex-coated Apg-Cu(II) SLNs exhibited the particle size of 374 ± 2.03 nm, surface charge of -25.6 ± 0.36 mV, and entrapment efficiency of 84.54 ± 0.05%. The formulation maintained robust stability in gastric and intestinal environments, triggering precise release upon exposure to colonic dextranase. Cu(II) complexation significantly enhanced the anticancer efficacy, lowered the IC
Indexed as
Identifiers
42365116What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.